[Alterations of serum lipoprotein (a) levels in continuous ambulatory peritoneal dialysis (CAPD) patients]

S Tanaka1

  • 1Department of Medicine, Juntendo University School of Medicine, Tokyo, Japan.

Insights

High lipoprotein (a) (Lp(a)) levels are a cardiovascular risk in continuous ambulatory peritoneal dialysis (CAPD) patients. This study found Lp(a) initially decreased then increased significantly over six months, linked to peritoneal excretion and liver production.

Area of Science:

  • Nephrology
  • Cardiovascular Science
  • Clinical Chemistry

Context:

  • Elevated plasma lipids, lipoproteins, and apolipoproteins are atherosclerosis risk factors in dialysis patients.
  • High serum lipoprotein (a) (Lp(a)) is an independent cardiovascular disease risk factor, particularly in continuous ambulatory peritoneal dialysis (CAPD) patients.

Purpose:

  • To investigate changes in serum Lp(a) levels in CAPD patients before and at 1, 3, and 6 months after initiating CAPD.

Summary:

  • Serum Lp(a) and LDL levels decreased one month post-CAPD initiation.
  • Significant increases in Lp(a), LDL, and various apolipoproteins were observed at 3 and 6 months.
  • Serum Lp(a) correlated with LDL, lipoprotein B, and serum albumin levels.
  • Peritoneal effluents contained substantial Lp(a), suggesting excretion and potential hepatic hyperproduction as causative factors.

Impact:

  • Findings highlight dynamic changes in Lp(a) during CAPD, impacting cardiovascular risk assessment.
  • Identifies Lp(a) excretion into peritoneal fluid and possible hepatic overproduction as key mechanisms.
  • Informs clinical management strategies for cardiovascular disease prevention in CAPD patients.